Evotec inks drug discovery deal with Genentech

Evotec has signed a multi-year integrated drug discovery alliance with Roche's Genentech to discover novel small molecule therapeutics. Evotec will use its integrated and innovative drug discovery platform against targets nominated by Genentech to identify development candidates. Financial details of the deal were not disclosed.

"We are proud that Genentech, one of the premier biopharmaceutical companies worldwide, has selected Evotec's scientists and innovative drug discovery platform to support their research efforts. We look forward to working closely with Genentech's scientists and achieving success together," says Dr. Werner Lanthaler, Evotec's CEO.

- check out Evotec's release

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.